Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02445963 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR)
A Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT02445963 is a Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 38 participants.
The verdict
NCT02445963, a Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
This study is an open-label, dose-escalating Phase 1 investigation of S. flexneri 2a InvaplexAR vaccine. A total of up to 40 subjects will receive one of four S. flexneri 2a InvaplexAR vaccine doses. The vaccine will be administered intranasally (without adjuvant).
Interventions
- BIOLOGICAL Shigella flexneri 2a InvaplexAR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2015-10-01 |
| Est. Completion | 2016-05-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02445963
The ClinicalTrials.gov registry entry for NCT02445963 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Shigella flexneri 2a InvaplexAR is the first listed.
NCT02445963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02445963 about?
NCT02445963 is a clinical study titled "Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR)". This study is an open-label, dose-escalating Phase 1 investigation of S. flexneri 2a InvaplexAR vaccine. A total of up to 40 subjects will receive one of four S. flexneri 2a InvaplexAR vaccine doses. The vaccine will be administered intranasally (without adjuvant).
What is the current status of trial NCT02445963?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2015-10-01. Estimated completion is 2016-05-13.
What interventions are being tested in trial NCT02445963?
The interventions under investigation include: Shigella flexneri 2a InvaplexAR (BIOLOGICAL).
Who is sponsoring clinical trial NCT02445963?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.